AGT 182

Drug Profile

AGT 182

Alternative Names: AGT182; IgG iduronate 2 sulfatase fusion protein; Insulin receptor MoAb-IDS fusion protein; Recombinant human insulin receptor monoclonal antibody-fused iduronate 2 sulfatase; SHP 631

Latest Information Update: 14 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ArmaGen Technologies
  • Class Iduronate sulfatases; Immunoglobulin fusion proteins; Monoclonal antibodies
  • Mechanism of Action Iduronate sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis II
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis II

Most Recent Events

  • 14 Aug 2017 AGT 182 is still in phase-I/II clinical trials in Mucopolysaccharidosis II in USA (IV) (NCT02262338) (ArmaGen pipeline, August 2017)
  • 14 Jul 2016 Efficacy and adverse events data from a phase I/IIa trial in Mucopolysaccharidosis II released by ArmaGen
  • 01 Mar 2015 Phase-I/II clinical trials in Mucopolysaccharidosis II in USA (IV) (NCT02262338)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top